Glenmark Pharmaceuticals Ltd. reported a 5.6% year-on-year (YoY) increase in revenue from operations for Q2 FY25, reaching ₹3,433.80 crore compared to ₹3,207.38 crore in Q2 FY24. On a quarter-on-quarter (QoQ) basis, the revenue rose by 5.8% from ₹3,223.30 crore in Q1 FY25.
In terms of profitability, Glenmark turned around from a net loss of ₹180.30 crore in Q2 FY24 to a net profit of ₹354.48 crore in Q2 FY25. Sequentially, the profit increased by 4.2% from ₹340.23 crore in Q1 FY25.
This turnaround and growth in revenue reflect the company’s strengthened financial position and operational performance.
